Dyadic International Inc
NASDAQ:DYAI

Watchlist Manager
Dyadic International Inc Logo
Dyadic International Inc
NASDAQ:DYAI
Watchlist
Price: 1.89 USD 8%
Market Cap: 55.9m USD
Have any thoughts about
Dyadic International Inc?
Write Note

Dyadic International Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dyadic International Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Dyadic International Inc
NASDAQ:DYAI
Total Current Assets
$10.7m
CAGR 3-Years
-23%
CAGR 5-Years
-22%
CAGR 10-Years
2%
Abbvie Inc
NYSE:ABBV
Total Current Assets
$27.8B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Assets
$13.1B
CAGR 3-Years
-2%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Total Current Assets
$26.8B
CAGR 3-Years
3%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Assets
$9.8B
CAGR 3-Years
3%
CAGR 5-Years
15%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Assets
$19.3B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
24%
No Stocks Found

Dyadic International Inc
Glance View

Market Cap
55.9m USD
Industry
Biotechnology

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.

DYAI Intrinsic Value
1.98 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Dyadic International Inc's Total Current Assets?
Total Current Assets
10.7m USD

Based on the financial report for Sep 30, 2024, Dyadic International Inc's Total Current Assets amounts to 10.7m USD.

What is Dyadic International Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
2%

Over the last year, the Total Current Assets growth was 18%. The average annual Total Current Assets growth rates for Dyadic International Inc have been -23% over the past three years , -22% over the past five years , and 2% over the past ten years .

Back to Top